Corporate Update We are excited to have moved our office to a new space! We are in the same building but at a new address: 21 Drydock Ave, 7th Floor, Boston, MA 02110. While we are managing the number of employees in our office at any given time due to the coronavirus pandemic, our reagent production and customer service have remained fully operational. You can regularly check our COVID response on our website here, where we list any new updates to our safety protocols, as well as our latest coronavirus research reagents.
Kerafast Blog Contest This summer we hosted a blog contest with the goal of giving college-age students aspiring to work in the life science industry the opportunity to explore a topic of their choosing and submit a blog post for our website. We were thrilled to receive many entries, all of which are posted on our blog! We wish all of these young scientists luck as they pursue their careers and would like to congratulate Maria Latacz for winning the $1,000 grand prize with her blog post titled Much Ado about Vitamin C.
New Kerafast Citations It’s always exciting to see our reagents cited in research publications. Recently our Yeast-Display Nanobody Library from Dr. Kruse at Harvard University was used to identify the most useful nanobodies for a Coronavirus study, in which the researchers developed a synthetic aerosol nasal spray that works to inhibit the viral entry of SARS-CoV-2 into human cells. We also saw our puromycin antibody cited in a Nature publication linking autism to the oxytocin signaling pathway in a mouse model. The puromycin antibody from Dr. Kimball at Penn State College of Medicine provides a non-radioactive method to measure rates of global protein synthesis.
If you have recently cited a Kerafast product in your research, let us know! We enjoy seeing the Kerafast community grow and would love to highlight your publication.
Featured Lab Benhur Lee, MD, Icahn School of Medicine at Mount Sinai The Lee Lab has a special interest in emerging viruses, with a focus on molecular viral-host interactions at the level of enveloped virus entry and budding mechanisms. They currently use HIV and henipaviruses as their primary model systems. In addition, Dr. Lee also has active projects translating insights gained from basic studies on host-pathogen interactions into broad-spectrum anti-viral therapeutics. Dr. Lee offers two Sendai Virus protein antibodies through our reagents catalog which can be used to study Sendai virus, a single-stranded RNA virus that replicates in the respiratory tract and primarily affects mammals.
SeqPack™ Hybridoma Preservation Kit Last month our sister company Absolute Antibody added the SeqPack™ Hybridoma Preservation Kit to their antibody sequencing service, streamlining the sample submission process by eliminating the need to ship hybridoma cells on dry ice. Antibody sequencing protects valuable antibodies from mutation or loss; with a known sequence, the same exact antibody can always be expressed with high batch-to-batch reproducibility. Antibody sequencing is also the first step toward antibody engineering and recombinant production. Learn more about sequencing your antibodies here.
We are excited to have moved our office to a new space! We are in the same building but at a new address: 21 Drydock Ave, 7th Floor, Boston, MA 02110. While we are managing the number of employees in our office at any given time due to the coronavirus pandemic, our reagent production and customer service have remained fully operational. You can regularly check our COVID response on our website 
This summer we hosted a blog contest with the goal of giving college-age students aspiring to work in the life science industry the opportunity to explore a topic of their choosing and submit a blog post for our website. We were thrilled to receive many entries, all of which are posted on our 
It’s always exciting to see our reagents cited in research publications. Recently our 
The Lee Lab has a special interest in emerging viruses, with a focus on molecular viral-host interactions at the level of enveloped virus entry and budding mechanisms. They currently use HIV and henipaviruses as their primary model systems. In addition, Dr. Lee also has active projects translating insights gained from basic studies on host-pathogen interactions into broad-spectrum anti-viral therapeutics. Dr. Lee offers two 
Last month our sister company Absolute Antibody added the 
